Word: patenting
(lookup in dictionary)
(lookup stats)
Dates: during 1990-1999
Sort By: most recent first
(reverse)
...Gore doesn't mince words when it comes to pushing for cheaper prescription drugs. So it makes sense that he opposes efforts by pharmaceuticals companies to extend their patent rights in order to block cheaper generic drugs from reaching the market...
What doesn't make sense is that one of Gore's senior advisers, top-tier lobbyist Peter Knight, is a hired gun for pharmaceuticals giant Schering-Plough, which is in a red-hot battle to stretch out its patent for the best-selling allergy medication Claritin beyond 2002. The New Jersey-based company paid Knight's firm $100,000 in the first half of this year alone...
...Patent extensions for drugs are rare. The last one, granted in 1996, was for the popular arthritis drug Daypro. So Schering-Plough has tried to work the system every way it can. First it wanted Congress to approve a straight extension of its patent. When that didn't fly, it tried a bill that would have shifted any patent-extension decision away from Congress to a new review board at the Patent and Trademark Office, and defined criteria for such extensions in ways that tended to favor the drug companies. But that bill, quietly introduced by New Jersey Senator Frank...
...often does around this time, Bob Martin, 47, is standing on his head. Martin has just finished another frenzied day as a patent attorney at Hewlett-Packard's Palo Alto, Calif., headquarters, but instead of plunging into rush-hour traffic, he has descended one flight of stairs to the company's yoga studio. Soft music flutes through the room as half a dozen practitioners, high heels and neckties stowed in nearby lockers, bend and breathe to their instructor's directions. "It's wonderful," Martin says, rolling back to his feet. "I come down here and I let everything that...
Nichols began calling pharmaceutical houses in the U.S. and Europe, telling them that if they started making sulindac it would save thousands of lives. But it was about to come off patent, and as a generic drug it didn't offer much of a payoff because of the likelihood of competitive products and lower prices. Moreover, FAP--Nichols' cancer--is a so-called orphan disease, afflicting only 25,000 Americans, so there wasn't much of a market for it. Thanks, but no thanks, the drugmakers said...